<DOC>
	<DOCNO>NCT00840632</DOCNO>
	<brief_summary>The objective study compare rate extent absorption trandolapril test formulation Trandolapril 4 mg Tablets versus reference Mavik® 4 mg Tablets fast condition .</brief_summary>
	<brief_title>Trandolapril 4 mg Tablet Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Trandolapril</mesh_term>
	<criteria>Inclusion Criteria Nonsmoking male female minimum age 18 year ( i.e . nonsmoker nontobacco user least 90 day prior prestudy medical screening ) . Body Mass Index ( BMI = weight/height2 ) great equal 19.0 kg.m2 less equal 30.0 kg/m2 . Normal finding physical examination , 12lead ECG vital sign ( blood pressure 100140/6090 mmHg , heart rate 50100 beats/min , temperature 35.8°C 37.5°C ) . Negative drug abuse , nicotine , hepatitis Bsurface antigen , hepatitis C HIV , female subject , pregnancy ( serum βCG ) . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . Female subject surgically sterile least six month postmenopausal least one year , avoid pregnancy prior study , study one month end study . Exclusion Criteria Known history hypersensitivity trandolapril ( e.g . Mavik® ) ACE inhibitor captopril , benazepril , enalapril , lisinopril , ramipril , quinapril , cilazapril angiotensin receptor agonists losartan , candesartan , eprosartan , irbesartan , telmisartan , valsartan . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless judge clinically significant Principal Investigator medical designate . Known history presence food allergy , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant illness last four week prior entry study . Presence significant physical organ abnormality . Any subject history drug abuse . Any history evidence psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator , medical designate . Use prescription medication within 14 day precede entry study . Use counter ( OTC ) medication within seven day precede entry study ( except spermicidal/barrier contraceptive product ) . Female subject : use contraceptive ( oral , transdermal , implant , Mirena® IUD ) within 30 day prior drug administration depot injection progestogen drug ( e.g . DepoProvera® ) within one year prior drug administration . Female subject : presence pregnancy lactation . Any subject blood drawn within 56 day precede study , take conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . Participation clinical trial investigational drug within 30 day precede study . Any subject donate blood within 56 day precede study . Any subject participate plasma donor plasmapheresis program within seven day precede study . Significant recent history asthma ( 12 year age ) . Any subject recent ( less one year ) history alcohol abuse . Known history frequent headache migraine . Known history hereditary idiopathic angioedema . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) . Intolerance venipuncture . Any clinically significant surgery within 4 week prior administration study medication . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoine , glucocorticoid , omeprazole , ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Difficulty swallow study medication . Difficulty fast consume standard meal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>